NZ613343B2 - Internal parasiticide - Google Patents
Internal parasiticide Download PDFInfo
- Publication number
- NZ613343B2 NZ613343B2 NZ613343A NZ61334312A NZ613343B2 NZ 613343 B2 NZ613343 B2 NZ 613343B2 NZ 613343 A NZ613343 A NZ 613343A NZ 61334312 A NZ61334312 A NZ 61334312A NZ 613343 B2 NZ613343 B2 NZ 613343B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- group
- halogen atom
- optionally substituted
- atom
- group optionally
- Prior art date
Links
- 230000000590 parasiticidal effect Effects 0.000 title 1
- 239000002297 parasiticide Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 9
- 244000079386 endoparasite Species 0.000 claims abstract 6
- 241001465754 Metazoa Species 0.000 claims abstract 3
- 125000005843 halogen group Chemical group 0.000 claims 56
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 34
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 20
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 125000004429 atom Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000004434 sulfur atom Chemical group 0.000 claims 7
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 238000010348 incorporation Methods 0.000 claims 4
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 3
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004844 (C1-C6) alkoxyimino group Chemical group 0.000 claims 2
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000005529 alkyleneoxy group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000001924 cycloalkanes Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 241000790917 Dioxys <bee> Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 244000000013 helminth Species 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003936 benzamides Chemical class 0.000 abstract 1
- 150000003857 carboxamides Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/73—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
Abstract
Disclosed herein is a method for controlling internal endoparasites by orally or parenterally administering to a non-human mammal or bird an effective amount of an endoparasite control agent comprising a carboxamide (i.e. benzamide) derivative represented by the general formula (I), wherein the variables are as defined in the specification. The compositions are suited to administration to humans and domestic animals to control protozoa and helminths. ables are as defined in the specification. The compositions are suited to administration to humans and domestic animals to control protozoa and helminths.
Description
HAS510030NZPR
303864625
DESCRIPTION
INTERNAL PARASITICIDE
TECHNICAL FIELD
The present invention relates an endoparasite control agent
comprising a carboxamide tive or a salt thereof as an
active ingredient, and a method for controlling endoparasites,
comprising orally or parenterally administering the
endoparasite control agent.
BACKGROUND ART
Certain kinds of carboxamide derivatives have been known
to have icidal activity (see Patent Literature 1 to 12).
However, there is no description indicating that these
compounds described in the literature are effective against
endoparasites in animals such as mammals and birds. Further,
it is known that certain kinds of carboxamide tive are
effective t nematodes that may damage agricultural
products (see Patent Literature 4 or 5), but there is no specific
disclosure on any effect against endoparasites in animals.
Furthermore, it has been reported that nds that inhibit
succinate-ubiquinone reductase (mitochondrial x II),
which is one of the respiratory enzymes of endoparasites, can
serve as an rasite control agent (see Non Patent
Literature 1).
CITATION LIST
Patent Literature
Patent Literature 1: JP—A 01—151546
Patent Literature 2: W0 2007/060162
Patent Literature 3: JP~A 53-9739
Patent Literature :
Patent Literature :
Patent Literature 6: WO 01975
Patent Literature 7:
Patent ture 8:
Patent Literature 9:
Patent Literature 10:
Patent Literature 11:
Patent Literature 12: W0 2010/106071
Non Patent Literature
Non Patent Literature 1:
Kiyoshi Kita, “Kansen (Infection)”, Winter 2010, Vol. 40—4,
310-319
SUMMARY OF INVENTION
TECHNICAL PROBLEM
lly, parasitosis is caused by parasites that have
infected and resided in host animals, and examples of the
parasites include unicellular protists (protozoa),
multioellular helminths and arthropods. It is reported that
the incidence of parasitosis in Japan has been remarkably
decreased by improvement of nmental hygiene, but on a
global scale, particularly in developing ies,
parasitosisstillwidelyprevailsandcausestremendousdamage.
In recent years, there has been an increasing trend in the
nce of parasitic infection due to introduction of
HAS510030NZPR
303864625
infection s via long- or short-term as travelers,
ingestion of food imports, ion of raw meat and fish meat
that are more available thanks to the advance in freezing and
logistics technologies, etc., and also in the incidence of
parasitosis from pets etc. Another problem is that
immunodeficiency caused by mass administration of
immunosuppressants, anticancer drugs, etc. or by AIDS etc.
allows usually non-pathogenic or low-pathogenic parasites to
express their pathogenicity and to cause opportunistic
infection in hosts. Further, tosis in ic animals,
such as pigs, horses, cattle, sheep, dogs, cats and domestic
fowls, is a universal and serious economic problem. That is,
parasitic infection of domestic animals causes anemia,
malnutrition, debility, weight loss, and serious damage of
intestinal tract walls, tissues and , and may result in
decline in feed efficiency and productivity, g to a great
economic loss. Therefore, novel endoparasite control agents
as a parasiticide, an antiprotozoal or the like have always been
desired.
OBJECT
It is an object of the present invention to provide a method
for controlling endoparasites and/or the use of a carboxamide
derivative represented by the general formula (I), or to at
least provide the public with a useful .
SOLUTION TO PROBLEM
The present inventors conducted extensive research to solve
the above-described problems. As a result, the present
inventors found that a carboxamide derivative represented by
HAS510030NZPR
303864625
the general formula (I) of the present ion, and a salt
thereof have a high control effect against endoparasites, and
then completed the present invention. That is, the present
invention relates to the following.
An endoparasite control agent comprising a carboxamide
derivative represented by the general formula (I):
(Y)n
(X)m GIN A-<Z
_ > (I)
{wherein A represents a (C1—C8) alkylene group optionally
substituted by a halogen atom, a (C1-C5) alkyl group and/or a
(C3—C5) cycloalkyl group; a (C1-C8) alkylene group which is
optionally substituted by a halogen atom, a (Cl—~06) alkyl group
and/or a (C3-C5) lkyl group and is modified by
incorporation, into the carbon chain, of at least one heteroatom
selected from an oxygen atom, a sulfur atom, -SO-, -SOZ~ and
-N(R)- (wherein R represents a en atom, a (C1-C6) alkyl
group, a (C3~C5) cycloalkyl group, a (C1-C5) alkylcarbonyl group
or a (Cl—C5) alkoxycarbonyl group); a (C2-C3) alkenylene group
optionally substituted by a halogen atom, a (C1—C6) alkyl group
and/or a (C3-C5) cycloalkyl group; a (C2-C3) lene group
which is ally substituted by a halogen atom, a (C1-C6)
alkyl group and/or a (C3—C5) cycloalkyl group and is ed
by incorporation, into the carbon chain, of at least one
atom selected from an oxygen atom, a sulfur atom, ~SO—,
-SOz- and —N(R)- (wherein R is as defined above); a )
alkynylene group ally substituted by a halogen atom, a
(C1—C6) alkyl group and/or a (C3-C5) cycloalkyl group; or a
(C2—C8) alkynylene group which is optionally substituted by a
halogen atom, a (Cl-Cs) alkyl group and/or a (C3~C5) cycloalkyl
group and is modified by incorporation, into the carbon chain,
of at least one heteroatom selected from an oxygen atom, a sulfur
atom, ~SO-, -SOz~ and —N(R)- (wherein R is as defined above),
and in each case, A may form a cyclic structure, where possible,
E represents a hydrogen atom; a (Cl-C6) alkyl group; a )
cycloalkyl group; a (C1-C6) alkoxy (C1-C6) alkyl group; a (Cl-Cs)
alkylcarbonyl group; or a (C1—C6) alkoxycarbonyl group,
each X may be the same or different
, and represents a halogen
atom; a cyano group; a nitro group; a (C1-C5) alkyl group
optionally tuted by a n atom; a (C1—C5) alkoxy group
optionally substituted by a halogen atom; a (C1-C5) hio
group optionally substituted by a halogen atom; a (C1—C5)
alkylsulfinyl group optionally tuted by a halogen atom;
or a (C1—C6) alkylsulfonyl group optionally substituted by a
halogen atom,
m represents an integer of 0 to 5,
each Y may be the same or different and ents a halogen
atom; a cyano group; a nitro group; a y group; a (C1-C6)
alkyl group optionally substituted by a halogen atom; a (C2-C5)
alkenyl group optionally substituted by a halogen atom; a
(C2-C5) alkynyl group optionally substituted by a halogen atom;
a (C1-C5) alkoxy group optionally substituted by a halogen atom;
a (C1—C6) alkoxy (C1~C5) alkoxy group; a (C2-C5) alkenyloxy group
optionally substituted by a halogen atom; a ) alkynyloxy
group optionally substituted by a halogen atom; a (C1-C6)
alkylthio group optionally substituted by a halogen atom; a
(C1-C5) alkylsulfinyl group optionally substituted by a n
atom; a (Cl—CG) alkylsulfonyl group optionally substituted by
a halogen atom; a ) alkoxycarbonyl group; a (C1—C6)
alkoxyimino (Cl-C3) alkyl group; a (C3—C30) trialkylsilyl group;
a mono(C1-C6) alkylsulfonylamino group optionally substituted
by a halogen atom; a phenyl group optionally substituted by one
or more substituents selected from group B substituents; a
phenoxy group optionally substituted by one or more
substituentsselectedfromgroupIBsubstituents;aheterocyclic
group optionally substituted by one or more substituents
selected from group B substituents; or a heterocycloxy group
optionally substituted by one or more substituents ed
from group B substituents,
the group B substituents are a halogen atom; a cyano group;
a nitro group; a (C1-C5) alkyl group ally substituted by
a.halogen atom; a ) l group optionally substituted
by a halogen atom; a (C2-C5) alkynyl group ally
substituted by a halogen atom; a (C1-C6) alkoxy group optionally
substituted by a halogen atom; a ) alkenyloxy group
optionally substituted by'a halogen atom; a (C2-C5) alkynyloxy
group optionally substituted by a halogen atom; a (014k)
alkylthio group optionally tuted by a halogen atom; a
(C1—C5) alkylsulfinyl group optionally substituted by a halogen
atom; a (C1—C6) alkylsulfonyl group optionally tuted by
a halogen atom; a (C1-C5) alkoxycarbonyl group; and a (C1—C5)
alkoxyimino (C1—C3) alkyl group,
n represents an r of O to 5, with the proviso that
when n is an integer of 2 to 5, two adjacent Y groups may join
together to form a (C3-C5) alkylene group; a (C3-C5) alkenylene
group; a (C2-C4) alkyleneoxy group; or a (C1-C3) alkylene dioxy
group optionally substituted by a halogen atom, and
Z represents a nitrogen atom; CH; or CY (wherein Y is as
defined above)}. or
a salt thereof as an active ingredient.
The endoparasite control agent according to the above [1] ,
wherein A represents a (C1-C3) alkylene group optionally
tuted by a halogen atom, a (Cy-C6) alkyl group and/or a
(C3-C5) cycloalkyl group; or a (Cl—Ca) alkylene group which is
optionally substituted by a halogen atom, a ) alkyl group
and/or a (C3-C5) cycloalkyl group and is modified by
incorporation, into the carbon chain, of at least one heteroatom
selected from an oxygen atom, a sulfur atom, -SO-, ~SOz- and
—N(R)- (wherein R represents a hydrogen atom, a ) alkyl
group, a (C3-C6) cycloalkyl group, a (C1-C6) alkylcarbonyl group
or a ) alkoxycarbonyl group).
The endoparasite control agent according to the above [1] ,
wherein A represents a (C1-C3) alkylene group optionally
tuted by a (C1-C5) alkyl group and/or a (C3-C5) cycloalkyl
group; ~CR1(R2)—CR3(R‘)-Q— (wherein R1, R2, R3 and R4 may be the
same or different from each other, and represent a en atom,
a (C1-C5) alkyl group or a (C3-C6) cycloalkyl group, or R1, R2,
R3 and R‘1 may join together in any combination to form a (C3-C6)
cycloalkane, and Q represents an oxygen atom, a sulfur atom,
-SO-, -SOz— or -N(R)- (wherein R represents a hydrogen atom,
a (C1—C5) alkyl group, a (C3-C5) lkyl group, a (C1-C5)
arbonyl group or a (C1—C6) alkoxycarbonyl group”; or
-CR1(R2)—CR3(R4)—CR5(R6)-Q— (wherein R1, R2, R3, R4 and Q are as
defined above, and R5 and R6 may be the same or different from
each other, and ent a hydrogen atom, a (C1—C6) alkyl group
or a (C3-C5) cycloalkyl group, or R1, R2, R3, R4, R5 and R6 may
join together in any combination to form a (C3—C6) cycloalkane) .
[4} The endoparasite control agent according to the above [1] ,
wherein A represents a (C1~C8) alkylene group optionally
substituted by a (C1-C6) alkyl group and/or a (C3-C5) cycloalkyl
group; —CR1(R2)-CR3(R4)—Q- (wherein R1, R2, R3 and R4 may be the
same or different from each other, and represent a hydrogen atom,
a (C1—C5) alkyl group or a (C3-C5) cycloalkyl group, or R1, R2,
R3 and R4 may join together in any ation to form a (C3-C6)
cycloalkane, and Q represents an oxygen atom, a sulfur atom,
~SO-, -SOz- or -N(R)- (wherein R represents a hydrogen atom,
a (C1-C5) alkyl group, a (C3-C5) cycloalkyl group, a (Cl-C5)
alkylcarbonyl group or a (C1—C5) carbonyl grouPH; or
-CR1(R2)-CR3(R4)~CR5(R6)-Q~ (wherein R1, R2, R3, R4 and Q are as
defined above, and R5 and R6 may be the same or different from
each other, and represent a en atom, a (C1-C6) alkyl group
or a (C3-C6) cycloalkyl group, or R1, R2, R3, R“, R5 and R6 may
join together in any combination to form a (C3-C5) cycloalkane) ,
E ents a hydrogen atom; a (C1-C5) alkyl group; a (C1-C6)
alkylcarbonyl group; or a (C1—C5) alkoxycarbonyl group,
each X may be the same or different and represents a halogen
atom; a (C1-C6) alkyl group optionally substituted by a halogen
atom; a (C1—C5) alkoxy group optionally substituted by a halogen
atom; or a (C1—C5) alkylthio group optionally substituted by
a halogen atom,
m represents 1 or 2,
each Y may be the same or ent , and represents a halogen
atom: a hydroxy group; a (C1‘”C6) alkyl group optionally
substituted by a halogen atom; a (C1—C6) alkoxy group optionally
substituted by a halogen atom; a (C1-C5) alkoxy (C1—C6) alkoxy
group; a ) loxy group optionally substituted by a
halogen atom; a mono(C1-C5) alkylsulfonylamino group optionally
substituted by a n atom; a phenyl group optionally
substituted by one or more substituents selected from a halogen
atom, a cyano group, a nitro group, a (C1—C5) alkyl group
optionally tuted by a halogen atom, and a ) alkoxy
group ally substituted by a halogen atom; a phenoxy group
optionally substituted by one or more substituents selected
from a halogen atom, a cyano group, a nitro group, a (Cl—C5)
alkyl group optionally substituted by a halogen atom, and a
) alkoxy group optionally substituted by a halogen atom;
a heterocyclic group ally substituted by one or more
substituents selected from a halogen atom, a cyano group, a
nitro group, a (C1—C5) alkyl group optionally substituted by
a halogen atom, and a (C1-C5) alkoxy group optionally
tuted by a halogen atom,- or a heterocycloxy group
optionally substituted by one or more substituents selected
from a halogen atom, a cyano group, a nitro group, a )
alkyl group optionally substituted by a halogen atom, and a
(C1-C6) alkoxy group optionally substituted by a halogen atom,
n ents an r of 0 to 3, with the proviso that
when n is 2 or 3, two adjacent Y groups may join together to
2O form a (C2-C4) alkyleneoxy group or a (C1-C3) alkylene dioxy group
optionally substituted by a halogen atom, and
Z represents a nitrogen atom; CH; or CY (wherein Y is as
defined above).
{5] The endoparasite control agent according to the above [1] ,
wherein A represents a (C1-C5) alkylene group optionally
substituted by a (C1"C5) alkyl group and/or a (C3-C6) cycloalkyl
group; —CR1(R2)—CR3(R4)—Q- (wherein R1, R2, R3 and R4 may be the
same or different from each other, and represent a hydrogen atom,
a (C1-C5) alkyl group or a (C3-C5) cycloalkyl group, and Q
HAS510030NZPR
303864625
represents an oxygen atom or a sulfur atom); or
-CR1(R2)-CR3(R4)-CR5(R6)-Q- in R1, R2, R3, R4 and Q are as
defined above, and R5 and R6 may be the same or different from
each other, and represent a hydrogen atom, a (C1-C6) alkyl group
or a ) cycloalkyl group),
E represents a hydrogen atom,
each X may be the same or ent, and represents a halogen
atom or a (C1-C6) alkyl group optionally substituted by a halogen
atom,
m represents 1,
each Y may be the same or ent, and represents a halogen
atom or a (C1-C6) alkyl group optionally substituted by a halogen
atom,
n ents an integer of 1 to 3, and
Z represents a en atom; CH; or CY (wherein Y is as
defined above).
A method for controlling endoparasites, comprising orally
or parenterally administering an effective amount of the
endoparasite control agent according to any one of the above
[1] to [5] to a non-human mammal or a bird.
A method for controlling endoparasites, comprising orally
or parenterally administering an effective amount of the
endoparasite control agent according to any one of the above
to [5] to a non-human mammal.
[8] The method according to the above [7], wherein the non-human
mammal is a domestic animal.
A method for controlling endoparasites, comprising orally
or erally administering to a non-human mammal or bird an
effective amount of an endoparasite
HAS510030NZPR
303864625
control agent comprising a carboxamide tive represented
by the general a (I):
wherein A represents a (C1-C8) alkylene group optionally
substituted by a halogen atom, a (C1-C6) alkyl group and/or a
(C3-C6) cycloalkyl group; a (C1-C8) alkylene group which is
optionally substituted by a halogen atom, a (C1-C6) alkyl group
and/or a ) cycloalkyl group and is modified by
incorporation, into the carbon chain, of at least one atom
selected from an oxygen atom, a sulfur atom, -SO-, -SO2- and
-N(R)- (wherein R represents a hydrogen atom, a (C1-C6) alkyl
group, a (C3-C6) cycloalkyl group, a (C1-C6) alkylcarbonyl group
or a (C1-C6) alkoxycarbonyl group); a (C2-C8) alkenylene group
optionally substituted by a halogen atom, a (C1-C6) alkyl group
and/or a ) cycloalkyl group; a (C2-C8) alkenylene group
which is optionally substituted by a halogen atom, a (C1-C6)
alkyl group and/or a (C3-C6) cycloalkyl group and is modified
by oration, into the carbon chain, of at least one
heteroatom selected from an oxygen atom, a sulfur atom, -SO-,
-SO2- and -N(R)- (wherein R is as defined above); a (C2-C8)
alkynylene group optionally substituted by a n atom, a
(C1-C6) alkyl group and/or a (C3-C6) cycloalkyl group; or a
(C2-C8) alkynylene group which is optionally substituted by a
halogen atom, a (C1-C6) alkyl group and/or a (C3-C6) lkyl
group and is modified by incorporation, into the carbon chain,
of at least one heteroatom selected from an oxygen atom, a sulfur
HAS510030NZPR
303864625
atom, -SO-, -SO2- and -N(R)- (wherein R is as defined above),
and in each case, A may form a cyclic structure, where possible,
E represents a hydrogen atom; a (C1-C6) alkyl group; a (C3-C6)
cycloalkyl group; a (C1-C6) alkoxy (C1-C6) alkyl group; a (C1-C6)
alkylcarbonyl group; or a (C1-C6) alkoxycarbonyl group,
each X may be the same or different, and represents a halogen
atom; a cyano group; a nitro group; a (C1-C6) alkyl group
optionally substituted by a halogen atom; a (C1-C6) alkoxy group
optionally substituted by a halogen atom; a ) hio
group optionally substituted by a halogen atom; a (C1-C6)
alkylsulfinyl group optionally substituted by a n atom;
or a (C1-C6) ulfonyl group optionally substituted by a
halogen atom,
m represents an integer of 0 to 5,
each Y may be the same or different, and represents a halogen
atom; a cyano group; a nitro group; a hydroxy group; a (C1-C6)
alkyl group optionally substituted by a halogen atom; a (C2-C6)
alkenyl group optionally substituted by a halogen atom; a
(C2-C6) alkynyl group optionally substituted by a halogen atom;
a (C1-C6) alkoxy group optionally substituted by a halogen atom;
a (C1-C6) alkoxy (C1-C6) alkoxy group; a (C2-C6) alkenyloxy group
optionally substituted by a halogen atom; a (C2-C6) alkynyloxy
group ally substituted by a halogen atom; a (C1-C6)
alkylthio group optionally substituted by a halogen atom; a
(C1-C6) alkylsulfinyl group optionally substituted by a halogen
atom; a (C1-C6) alkylsulfonyl group optionally tuted by
a n atom; a ) alkoxycarbonyl group; a (C1-C6)
alkoxyimino (C1-C3) alkyl group; a 0) trialkylsilyl group;
a mono(C1-C6) alkylsulfonylamino group ally substituted
HAS510030NZPR
303864625
by a halogen atom; a phenyl group optionally substituted by one
or more tuents selected from group B substituents; a
phenoxy group optionally substituted by one or more
substituents selected from group B substituents; a heterocyclic
group optionally substituted by one or more substituents
selected from group B tuents; or a heterocycloxy group
optionally substituted by one or more substituents selected
from group B substituents,
the group B substituents are a n atom; a cyano group;
a nitro group; a (C1-C6) alkyl group optionally substituted by
a halogen atom; a (C2-C6) alkenyl group optionally substituted
by a halogen atom; a (C2-C6) alkynyl group optionally
substituted by a halogen atom; a (C1-C6) alkoxy group optionally
tuted by a halogen atom; a (C2-C6) alkenyloxy group
optionally tuted by a halogen atom; a (C2-C6) alkynyloxy
group optionally substituted by a halogen atom; a (C1-C6)
alkylthio group optionally substituted by a halogen atom; a
) alkylsulfinyl group optionally substituted by a halogen
atom; a (C1-C6) alkylsulfonyl group optionally substituted by
a halogen atom; a (C1-C6) alkoxycarbonyl group; and a (C1-C6)
imino (C1-C3) alkyl group,
n represents an r of 0 to 5, with the proviso that
when n is an integer of 2 to 5, two adjacent Y groups may join
together to form a ) alkylene group; a (C3-C5) alkenylene
group; a (C2-C4) alkyleneoxy group; or a (C1-C3) alkylene dioxy
group optionally substituted by a halogen atom, and
Z represents CH or CY (wherein Y is as defined above), or
a salt thereof as an active ingredient.
A method for controlling endoparasites, comprising orally
HAS510030NZPR
or parenterally administering an effective amount of the
non-human mammal or bird endoparasite control agent as defined
in [9] to a non-human mammal.
ADVANTAGEOUS EFFECTS OF INVENTION
The present invention provides a compound useful as an
endoparasite control agent which excels in performance as
ed with the tional art.
DESCRIPTION OF EMBODIMENTS
The definitions in the general formula (I) representing the
carboxamide derivative of the present ion are bed
below.
The “(Cl—Ca) alkylene group” refers to a straight C1-C3
alkylene group, for example, a methylene group, an ethylene
group, a trimethylene group, a tetramethylene group, a
pentamethylene group, a.hexamethylene group, a.heptamethylene
group, an octamethylene group or the like. In the “(Cl—Cg)
alkylene group optionally substituted by a halogen atom, a
(C1-C6) alkyl group or a (C3-C5) cycloalkyl group,” each
substituent may be bound to any carbon atom in the alkylene group.
The “(Cl—Ca) ne group which is optionally substituted by
a halogen atom, a (C1~C5) alkyl group or a (C3—C5) cycloalkyl
group and.is modified.by incorporation, into the carbon chain,
of at least one heteroatom selected from an oxygen atom, a sulfur
atom, -SO-, —SOz— and —N(R)—” refers to a group which is the
same as the above-mentioned optionally substituted straight
(C1-C3) alkylene group except for having such a heteroatom
attached to a terminal carbon atom or inserted between carbon
atoms in the alkylene group. The specific examples include an
ethyleneoxy'group, an.ethylenethio group, an.ethylene sulfinyl
group, an ethylene sulfonyl group, an ethylene amino group, a
eneoxy group, a propylenethio group , a propylene sulfinyl
group, a propylene sulfonyl group, a propylene amino group,
~CH2-CH2-O-CH2—, ~CH2~CH2—S-CH2- and -CH2-CH2-NH-CH2-.
The “(Cg—Cg) alkenylene group” refers to a straight (CZ-Ca)
lene group having one or more double bonds therein, for
example, a vinylene group, a propenylene group, a butenylene
group, a butadienylene group, a pentenylene group, a
pentadienylene group , a hexenylene group , a hexadienylene group,
a heptenylene group, a heptadienylene group, an octenylene
group, an octadienylene group or the like. In the “(C2-C3)
lene group optionally substituted by a halogen atom, a
(Cl-C5) alkyl group or a (C3-C5) cycloalkyl group,” each
substituent may be bound to any carbon atom in the alkenylene
group. The ) alkenylene group which is optionally
tuted by a halogen atom, a (Cl-C6) alkyl group or a (C3-C5)
cycloalkyl group and is modified by incorporation, into the
carbon chain of at least one heteroatom selected from an oxygen
atom, a sulfur atom, -SO-, -SOr-and ~N(R)w” refers to a group
which is the same as the above-mentioned optionally substituted
straight (CZ—C8) alkenylene group except for having such a
heteroatom ed to a terminal carbon atom or inserted
between carbon atoms in the alkenylene group. The specific
examples include a vinyleneoxy group, a nethio group, a
vinylene sulfinyl group, a‘vinylene sulfonyl group, a vinylene
amino group, a propenyleneoxy group, a propenylenethio group,
a propenylene sulfinyl group, a propenylene yl group, a
propenylene amino group, -CH=CH~CH¢O~CHz-, -CH=CH—CH2-S-CH2-
and —CH=CH-CH2-NH-CH2-.
The “(CZ—Cg) alkynylene group” refers to a straight C2-C8
alkynylene group having one or more triple bonds therein, for
example, an ethynylene group, a propynylene group, a butynylene
group, a butadiynylene group, a pentynylene group, a
pentadiynylene group , a hexynylene group, a hexadiynylene group ,
a heptynylene group, a heptadiynylene group, an ootynylene
group, an octadiynylene group or the like. In the “(CZ-Ca)
alkynylene group optionally tuted by a halogen atom, a
(C1—C5) alkyl group or a (C3—C5) cycloalkyl group,” each
substituent may be bound to any carbon atom in the alkynylene
group. The “(CZ—Ca) alkynylene group which is ally
substituted by a halogen atom, a ) alkyl group or a (C3-C5)
cycloalkyl group and is modified by incorporation, into the
carbon chain, of at least one heteroatom selected from an oxygen
atom, a sulfur atom, —SO—, —SOz- and -N(R)-” refers to a group
which is the same as the mentioned optionally substituted
straight (C2-C3) alkynylene group except for having such a
heteroatom attached to a terminal carbon atom or inserted
between carbon atoms in the alkynylene group. The specific
examples include an ethynyleneoxy group, an ethynylenethio
group, an ethynylene sulfinyl group, an ethynylene sulfonyl
group, an ethynylene amino group, a yleneoxy group, a
propynylenethio group, a propynylene sulfinyl group, a
ylene sulfonyl group, a propynylene amino group,
H2-O-CH2-, -CEC-CHz-S-CH2- and ~CECwCH2—NH-CH2-.
The “halogen atom” refers to a chlorine atom, a bromine atom,
an iodine atom or a fluorine atom. The “(C1-C5) alkyl group”
refers to a straight or ed alkyl group of l to 6 carbon
atoms, for example, a methyl group, an ethyl group, a n-propyl
group, an isopropyl group, a n—butyl group, an isobutyl group,
a sec—butyl group, a tert-butyl group, a n-pentyl group, a
neopentyl group, a n—hexyl group or the like.
The “ ) alkyl group optionally substituted by a halogen
atom” refers to a straight or branched alkyl group of 1 to 6
carbon atoms, for example, a methyl group, an ethyl group, a
n-propylgroup,anisopropylgroup,arrbutylgroup,anisobutyl
group, a sec-butyl.group, a tert—butyfl.group, a11-pentyl.group,
entyl group, a.n~hexyl group or‘the like; and.also refers
to a ht or branched alkyl group of l to 6 carbon atoms
substituted by one or more halogen atoms which.may be the same
or different from each other, for example, a trifluoromethyl
group, a romethyl group, a perfluoroethyl group, a
hexafluoroisopropyl group, a perfluoroisopropyl group, a
chloromethyl group, a bromomethyl group, a oethyl group,
a 2,3—dibromopropyl group or the like.
The “(CZ-Ca) alkenyl group optionally substituted by a
halogen atom” refers to a straight or branched alkenyl group
of 2 to 6 carbon atoms, for example, a.vinyl group, a propenyl
group, a butenyl group or the like; and also refers to a straight
or branched alkenyl group of 2 to 6 carbon atoms substituted
by one or~more halogen atoms whichlnay be the same or different
from each other, for example, a fluorovinyl group, a
difluorovinyl group, a orovinyl group, a
3 , 3 ~dichloropropenyl group , a 4 , 4 —difluoro— 3 ~butenyl group
or the like.
The “(CZ—Cs) alkynyl group optionally substituted by a
halogen atom” refers to a ht or branched alkynyl group
of 2 to 6 carbon atoms, for example, an ethynyl group, a propynyl
group, a butynyl group or the like; and also refers to a straight
or branched alkynyl group of 2 to 6 carbon atoms substituted
by one or more n atoms which may be the same or different
from each other, for example, a fluoroethynyl group, a
perfluoropropynyl group, a 4 , 4, 4-trifluoro-2—butynyl group or
the like.
The “(Cl-Ce) alkoxy group ally substituted by a
halogen atom” refers to a straight or branched alkoxy group of
l to 6 carbon atoms, for example, a methoxy group, an ethoxy
group , a oxy group , an isopropoxy group, a n—butoxy group ,
a sec-butoxy group, a tert-butoxy group, a n—pentyloxy group,
an isopentyloxy group
, a neopentyloxy group, a n~hexyloxy group
or the like ; and also refers to a ht or branched alkoxy
group of l to 6 carbon atoms substituted by one or more halogen
atoms which may be the same or different from each other, for
example, a trifluoromethoxy group, a difluoromethoxy group, a
perfluoroethoxy group, a perfluoroisopropoxy group, a
chloromethoxy group, a ethoxy group, a l—bromoethoxy
group, a 2,3-dibromopropoxy group or the like.
The “(C1~C5) alkoxy (C1-C6) alkoxy group” refers to a
straight or branched alkoxy group of l to 6 carbon atoms having
a straight or branched alkoxy group of 1 to 6 carbon atoms as
a substituent at a substitutable position, for example, a
methoxymethoxy group , an ethoxymethoxy group , a
l-methoxyethoxy group, a 2-methoxyethoxy group, a
l-ethoxyethoxy group, a 2~ethoxyethoxy group or the like.
The “ (C1-C5) alkoxy (C1—C5) alkyl group” refers to a straight
or branched alkyl group of 1 to 6 carbon atoms having a straight
or branched alkoxy group of 1 to 6 carbon atoms as a substituent
at a substitutable position, for example, a methoxymethyl group,
an methyl group, a l—methoxyethyl group, a 2-methoxyethyl
group , a l~ethoxyethyl group , a 2-ethoxyethyl group or the like.
The “(CZ-Ca) alkenyloxy group optionally tuted by a
halogen atom” refers to a ht or branched loxy group
of 2 to 6 carbon atoms, for example, a propenyloxy group, a
loxy group, a pentenyloxy group or the like; and also
refers to a straight or branched alkenyloxy group of 2 to 6 carbon
atoms substituted by one or more halogen atoms which may be the
same or different from each other, for example
, a fluorovinyloxy
group, a difluorovinyloxy group, a perfluorovinyloxy group, a
3,3-dichloropropenyloxy group, a
4 , 4 oro- 3 ~butenyloxy group or the like .
The “(CZ—Cs) alkynyloxy group optionally substituted by a
halogen atom” refers to a straight or branched alkynyloxy group
of 2 to 6 carbon atoms, for example, a propynyloxy group, a
butynyloxy group, a pentynyloxy group or the like; and also
refers to a straight or branched alkynyloxy group of 2 to 6 carbon
atoms substituted by one or more halogen atoms which may be the
same or different from each other, for example, a
fluoroethynyloxy group, a perfluoropropynyloxy group, a
4,4,4~trifluoro-2—butynyloxy group or the like.
The “(Cl-Cs) alkylthio group optionally substituted by a
halogen atom” refers to a straight or branched alkylthio group
of 1 to 6 carbon atoms, for example, a methylthio group, an
hio group, a n-propylthio group, an isopropylthio group,
a n-butylthio group, a sec-butylthio group, a tert—butylthio
group, a n-pentylthio group, an isopentylthio group, a
n—hexylthio group or the like; and also refers to a straight
or branched alkylthio group of l to 6 carbon atoms substituted
by one or more halogen atoms which may be the same or different
from each other, for example, a trifluoromethylthio group, a
romethylthio group, a perfluoroethylthio group, a
perfluoroisopropylthio group, a chloromethylthio group, a
bromomethylthio group a l - bromoethylthio
, group,
2,3-dibromopropylthio group or the like.
The “(C1~C5) alkylsulfinyl group optionally substituted by
a halogen atom” refers to a straight or branched alkylsulfinyl
group of l to 6 carbon atoms , for example, a methylsulfinyl group,
an ethylsulfinyl group, a n-propylsulfinyl group, an
pylsulfinyl group, a n-butylsulfinyl group, a
sec—butylsulfinyl group, a tert-butylsulfinyl group, a
n-pentylsulfinyl group, an isopentylsulfinyl group, a
n~hexylsulfinyl group or the like; and also refers to a ht
or branched alkylsulfinyl group of l to 6 carbon atoms
substituted by one or more halogen atoms which may be the same
or ent from each other , for example , a
trifluoromethylsulfinyl group , a difluoromethylsulfinyl group,
a perfluoroethylsulfinyl group, a perfluoroisopropylsulfinyl
group, a methylsulfinyl group, a bromomethylsulfinyl
group,
a 1 ~ bromoethylsulfinyl
group, a
2,3-dibromopropylsulfinyl group or the like.
The “(Cy-C5) alkylsulfonyl group optionally substituted by
a halogen.atom” refers to a straight or branched ulfonyl
group of l to 6 carbon atoms , for example, a methylsulfonyl group,
an ethylsulfonyl group, a n-propylsulfonyl group, an
isopropylsulfonyl group, a n-butylsulfonyl group, a
sec~butylsulfonyl group, a tert-butylsulfonyl group, a
ylsulfonyl group, an isopentylsulfonyl group, a
n-hexylsulfonyl group or the like; and also refers to a straight
or branched alkylsulfonyl group of l to 6 carbon atoms
substituted by one or more halogen atoms which may be the same
or different from each other , for example , a
trifluoromethylsulfonyfl.group,21difluoromethylsulfonyfl.group,
a perfluoroethylsulfonyl group, a oroisopropylsulfonyl
group, a chloromethylsulfonyl group, a bromomethylsulfonyl
group , a 1 - bromoethylsulfonyl
group, a
2,3-dibromopropylsulfonyl group or the like.
The “(Cl-Cs) alkylcarbonyl group” refers to a straight or
branched alkyl group of l to 6 carbon atoms bound to a carbonyl
group, for e, a methylcarbonyl group, an ethylcarbonyl
group, a n—propylcarbonyl group, an isopropylcarbonyl group,
a n-butylcarbonyl group, a tert—butylcarbonyl group or the
like.
The “( C1-C5) alkoxycarbonyl group" refers to a straight or
branched alkoxy group of l to 6 carbon atoms bound to a carbonyl
group, for example, a methoxycarbonyl group, an ethoxycarbonyl
group , a n—propoxycarbonyl group , an isopropoxycarbonyl group,
a n~butoxycarbonyl group, a tert-butoxycarbonyl group or the
like .
The “(Cl-c5) alkoxyimino (C1~C3) alkyl group” refers to a
straight or branched alkoxy group of 1 to 6 carbon atoms bound
to an imino ) alkyl group, for example, a methoxyimino
methyl group, an ethoxyimino methyl group, a n-propoxyimino
methyl group, an isopropoxyimino ethyl group or the like.
The “(C3-C3o) trialkylsilyl group” refers to a ht or
branched alkylsilyl group of 3 to 30 carbon atoms in total, for
example, a trimethylsilyl group, a triethylsilyl group or the
like .
The “mono(C1-C5) alkylsulfonylamino group optionally
substituted by a halogen atom” refers to a straight or branched
kylsulfonylamino group of 1 to 6 carbon atoms , for example,
a methylsulfonylamino group, an ethylsulfonylamino group, an
isopropylsulfonylamino group or the like ; and also refers to
a straight or branched monoalkylsulfonylamino group of l to 6
carbon atoms substituted by one or more halogen atoms which may
be the same or different from each other, for e, a
oromethylsulfonylamino group or the like.
The “(c3—c6) cycloalkane” that R1, R2, R3 and R4 may join
together in any combination to form and the “(Ca—Cs)
lkane” that R1, R2, R3, R4, R5 and R6 may join together in
any combination to form are, for example, cyclopropane,
utane, cyclopentane, cyclohexane or the like.
Examples of the “ (C2 -C4) alkyleneoxy group” include
"CH2'CH2‘O', 'CH2“C(CH3)2-O-, -CH2-CH2-CH2-O* and
H2-CH2-CH2~O~ .
The “ (C1~C3) alkylene dioxy group optionally tuted by
a halogen atom” refers to an alkylene dioxy group of 1 to 3 carbon
atoms, for example, ~O-CH2-O-, -O-CH2-CH2-O~, ~O~CH2~CH2—CHz-O-
or the like; and also refers to an alkylene dioxy group of 1
to 3 carbon atoms substituted by one or more halogen atoms which
may be the same or different from each other, for example,
~0~CF2-O—, ~O-CF2-CF2-O-, -O-CC12~O— or the like.
The “heterocyclic group" refers to a 5— or 6—membered
monocyclic aromatic or 3- or 6-membered monocyclic non—aromatic
heterocyclic group containing, as ring atoms , a carbon atom(s)
and 1 to 4 heteroatoms selected from an oxygen atom, a sulfur
atom and a nitrogen atom; and also refers to a condensed
heterocyclic group formed by condensation of such a monocyclic
aromatic or non-aromatic cycle with a benzene ring or by
condensation of such monocyclic aromatic or non-aromatic
heterocycles (the heterocycles may be different from each
other).
Examples of the “aromatic cyclic group” e
monocyclic aromatic heterocyclic groups , such as furyl , thienyl ,
pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl,
imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, yl,
isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl
andtriazinyl;andaromaticcondensedheterocyclicgroups,such
as quinolyl, isoquinolyl, olyl, quinoxalyl,
benzofuranyl, benzothienyl, azolyl, benzisoxazolyl,
benzothiazolyl, benzimidazolyl, benzotriazolyl, l,
lyl, opyrazinyl, imidazopyridinyl,
imidazopyrazinyl, pyrazolopyridinyl, pyrazolothienyl and
pyrazolotriazinyl.
Examples of the “non-aromatic heterocyclic group” include
monocyclic non-aromatic heterocyclic groups , such as oxiranyl,
thiiranyl, aziridinyl, oxetanyl, thietanyl, azetidinyl,
pyrrolidinyl, piperidinyl, linyl, thiomorpholinyl,
piperazinyl, hexamethyleneiminyl, oxazolidinyl,
thiazolidinyl, imidazolidinyl, oxazolinyl, thiazolinyl,
imidazolinyl, dioxolyl, dioxolanyl, dihydrooxadiazolyl,
2—oxo~1,3—oxazolidin~5—yl, pyranyl, tetrahydropyranyl,
thiopyranyl, tetrahydrothiopyranyl, l-oxide
tetrahydrothiopyranyl, 1,1~dioxide tetrahydrothiopyranyl,
tetrahydrofuryl, dioxanyl, pyrazolidinyl, pyrazolinyl,
tetrahydropyrimidinyl, dihydrotriazolyl and
tetrahydrotriazolyl; and non-aromatic condensed.heterocyclic
groups, such as oindolyl, dihydroisoindolyl,
dihydrobenzofuranyl, dihydrobenzodioxinyl,
obenzodioxepinyl, tetrahydrobenzofuranyl, chromenyl,
dihydroquinolinyl, tetrahydroquinolinyl,
dihydroisoquinolinyl, tetrahydroisoquinolinyl and
dihydrophthalazinyl.
Examples of a salt of the carboxamide derivative ented
by the general formula (I) of the present invention include
inorganic acid salts , such as hydrochlorides, sulfates ,
nitrates and phosphates; organic acid salts, such as acetates,
fumarates , maleates , oxalates , methanesulfonates
benzenesulfonates and p-toluenesulfonates; and salts with an
inorganic or organic base such as a sodium ion, a potassium ion,
a m ion and a trimethylammonium ion.
As the carboxamide derivative of the present invention,
preferred is a compound of the general a (I) wherein A
represents a (C1—C8) alkylene group optionally substituted by
a (Cl—Ca) alkyl group and/or a (C3~C6) cycloalkyl group;
—CR1(R2)—CR3(R4)—Q— (wherein R1, R2, R3 and R4 may be the same
or different from each other, and represent a hydrogen atom,
a (Cl-C5) alkyl group or a (C3-C5) cycloalkyl group, or R1, R2,
R3 and R‘1 may join together in any combination to form a (C3~C6)
cycloalkane, and Q represents an oxygen atom, a sulfur atom,
-SO-, -SO;- or —N(R)- (wherein R represents a hydrogen atom,
a (C1—C6) alkyl group, a (C3-C5) cycloalkyl group, a (C1-C5)
arbonyl group or a (C1-C5) alkoxycarbonyl ; or
2)-CR3(R4)-CR5(R6)-Q- (wherein R1, R2, R3, R‘ and Q are as
defined above, and R5 and R6 may be the same or different from
each other, and represent a hydrogen atom, a (C1-C6) alkyl group
or a (C3-C6) cycloalkyl group, or R1, R2, R3, R4, R5 and R6 may
join together in any ation to form a (C3-C5) cycloalkane) ,
E represents a hydrogen atom; a (C1-C5) alkyl group; a (C1-C6)
alkylcarbonyl group; or a (Cl-C6) alkoxycarbonyl group,
each X may be the same or ent , and represents a halogen
atom; a (Cl-C5) alkyl group optionally substituted by a halogen
atom; a (C1-C5) alkoxy group optionally substituted by a halogen
atom; or a (C1-C6) alkylthio group ally substituted by
a n atom.
m ents 1 or 2,
each Y may be the same or different , and represents a halogen
atonn a. hydroxy group; a (C1-C5) alkyl group optionally
substituted by a halogen atom; a (Cl-C5) alkoxy group optionally
substituted by a n atom; a (C1-C5) alkoxy (C1—C5) alkoxy
group; a (C2-C6) alkenyloxy group optionally substituted by a
halogen atom; a mono( C1-C5) alkylsulfonylamino group optionally
substituted by a halogen atom; a phenyl group optionally
substituted by one or more substituents selected from a halogen
atom, a cyano group, a nitro group, a (C1-C6) alkyl group
optionally substituted by a halogen atom, and a (C1—C5) alkoxy
group optionally tuted by a halogen atom; a phenoxy group
optionally substituted by one or more substituents selected
2O from a halogen atom, a cyano group, a nitro group, a (C1-C6)
alkyl group optionally substituted by a n atom, and a
(C1—C5) alkoxy group ally substituted.by a.halogen atom;
a heterocyclic group optionally substituted by one or more
substituents selected from a halogen atom, a cyano group, a
nitro group, a (C1—C6) alkyl group optionally substituted by
a halogen atom, and a (C1~C6) alkoxy group optionally
substituted by a halogen atom; or a heterocycloxy group
optionally tuted by one or more substituents selected
from a halogen atom, a cyano group, a nitro group, a (Cl-Ce)
alkyl group optionally substituted by a halogen atom, and a
(Cl—Cs) alkoxy group optionally substituted by a halogen atom,
n represents an integer of O to 3, with the proviso that
when n is 2 or 3, two nt Y groups may join together to
form a (C2—C4) alkyleneoxy group or a (C1-C3) alkylene dioxy group
optionally substituted by a halogen atom, and
2 ents a nitrogen atom; CH,- or CY (wherein Y is as
defined above).
More preferred is a compound of the general formula (I)
wherein A represents a (C1—C5) alkylene group optionally
substituted by a (C1-C6) alkyl group and/or a ) cycloalkyl
group; -CR1(R2)-CR3(R‘)~Q~ (wherein R1, R2, R3 and IR4 may be the
same or ent from each other, and represent a hydrogen atom,
a (C1-C5) alkyl group or a (C3—C5) cycloalkyl group, and Q
represents an oxygen atom or a sulfur atom); or
-CR1(R2)-CR3(R4)-CR5(R6)-Q- (wherein R1, R2, R3, R4 and Q are as
defined above, and R5 and R6 may be the same or different from
each other, and represent a hydrogen atom, a (C1~C6) alkyl group
or a (C3-C5) lkyl group),
E represents a hydrogen atom,
each X may be the same or different , and represents a halogen
atom or a (Cl-Cs) alkyl group optionally substituted by a halogen
atom,
m ents 1,
each Y may be the same or different , and represents a halogen
atom or a (C1—C6) alkyl group optionally tuted by a halogen
atom ,
n represents an integer of 1 to 3, and
Z represents a nitrogen atom; CH; or CY (wherein Y is as
defined above) .
The nd represented by the general formula (I) of the
present invention is a known compound, and can be produced by
the production method described in JP—A 01-151546, WO
2007/060162, JP-A 53—9739, , W0 2008/101975, WO
2008/101976, , , ,
W0 2009/127718 or WO 06071, the method described in
Shin—Jikken Kagaku Kouza 14 (Maruzen, December 20, 1977), a
ed method of the foregoing, or the like.
Representative examples of the carboxamide derivative
represented by the general formula (I) of the t invention
are shown in Table l, but the present invention is not limited
thereto. In Table 1, “Me” represents a methyl group, “Et”
represents an ethyl group, “Pr" represents a propyl group, “Bu”
represents a butyl group, “Ph” represents a phenyl group, “0-”
represents cyclo, “i-” represents iso , “t-” represents ry,
and the physical property refers to a melting point (°C) .
Regarding the compounds shown with the note ” in the
column “Physical property” in Table l
, their 1HNMR spectrum data
are shown in Table 5. Q1 to Q7 represent the following
structures.
C1 fie;
Q19 0 l‘v—/ CF3 23 O 1\‘J/ CF3 Q3, 0 Cl
3 s
(27, 0—(N'/
(X) -- H R3 R4
m N
(1—1)
() 111112 “-(an
Table 1
---flflfl_-
“mu——
--nnnn——
—---——n
-n-m-_n
”mum
mama
_--fl--——
-—-——nun
“mun
—-n--—_n
1-13 2—I H H Me Et 4-Cl Paste
—--——nn
“nun—-
—----——n
manna
--nnnn——
“mun
manna——
-—-_—nnu
--—-nnn
“unn-—_
--n-n-—
”mama
“I—flflfl
—-nnnn_
mun“
Table 1 (Continued)
--Iflflfl
“nun“ -
“III—H
“man—-
”———
“nu——
—-_—nnu
-I-—_
mun——
mun——
"mun
—m:flflfl__144 2, 4--Clz 124- 126
“—flflflfl—
—-IIII—-
-———IIII
—IIII—_
I—--I-——
_-——IIII
——IIII——
—_Il——II
—-IIII——
--I_II—
—-IIII—-
————IIII
—-lI——II
—-IIII——
Table 1 (Continued)
--"--
-II—I_
”IIII-
“II—mn—
——IIII——.
——IIII——.
————IIII
-IIII——
--II__II
—-II—-II
—-IIII——
—-I—III-
“II—flu-
——n:n-n——1-74 2CF3 2---Cl4Q5
“mu-n”
mann—
Emu—n—
manna——
“mama——
“mama——
---mnn——
“m-nn——
“man——
“an—
mann—
“MIME——
—-mmnu—-
”mn_—
Table 1 (Continued)
“HIE-u
man-
“In——
---_-
—-n-—nu—
mun—
—-----n_
”ma—
-—--—nn—
”unan—
mu--—_
“Inna——
1—- 104 2--CF;, 2-Cl- 4- SOMe 128. 9- 129. 6
unnu—
——n-nn——
-fl-fl—
“-nnn"
--n-n-—_
“Inna—-
“n-mm—_
mm—(erHYO‘)“ <12)
0R1 R2
Table 2
-”--
”nu—
———-nn
_n”—-
“nu——
-—-—-n
—-—_nn
—-———n
(X)m-O\K§ Y1
”a (1—3) 0 N
Table 3
(X)m Y Y property
value
—u-—
--——n
x m— H R3 R4 -m1]
0 R1 R2
Table 4
"Iflflfl—n
"II-“l-
nnll
“nun——
lama
m-mnn
“mu-u
----—_nn
mum——
ul-nn-mn——
"annual-—
Table 5
Com 0 nd
7.65(dd, 1H), 7.51(m, 2H), 7.32(dd, 1H), 7.30(d, 2H),
7.14(d, 2H), 5.58(br, 1H), 3.92(m, 1H), , 1H),
2.80(m, 1H), l.79(m,1H), 1.60(m, 1H), 0.83(t, 3H)
7.65(d, 1H), 7.51(m, 2H), 7.25-7.36(m, 5H), 5.40(br, 1H),
d, 1H), 3.59(dd, 1H), l.80(m, 1H), 1.66(m, 1H),
1.37(s, 3H), 0.74(t, 3H)
7.65(dd, 1H), 7.51(m, 2H), 7.26-7.37(m, 5H), 5.31(br, 1H),
, 2H), l.75(m, 4H), 0.79(t, 6H)
7.65(dd, 1H), 7.51(m, 2H), 7.32(dd, 1H), 7.29(d, 2H),
, 2H), 5.56(br, 1H), 3.87(m, 1H), 3.33(m, 1H),
2.98(m, 1H), 1.53(m, 2H), l.40(m, 1H), 0.87(t, 6H)
7.81(dd, 1H), 7.27-7.34(m, 5H), 7.22(dd, 1H), 7.05(dt, 1H),
.43(br, 1H), 3.76(dd, 1H), 3.61(dd, 1H), , 1H),
l.68(m, 1H), l.4l(S, 3H), , 3H)
7.81(dd, 1H), 7.30~7.35(m, 5H), 7.22(dd, 1H), 7.06(dt, 1H),
.34(br, 1H), 3.75(d, 2H), l.78(m, 4H), O.81(t, 6H)
7.70(d, 1H), , 1H), 7.53(t, 1H), 7.46(d, 1H),
7.4D(s, 1H), 7.39(d, 1H), 7.30(d, 1H), 5.86(br, 1H),
3.7l(dd, 2H), 3.00(t, 2H), 2.44(S, 3H)
7.69(d, 1H), 7.47-7.60(m, 3H), 7.36(t, 2H), 7.24(d, 1H),
7.15(t, 1H), 7.00—7.03(m, 3H), 6.88(dd, 1H), 5.85(br, 1H),
3.73(q, 2H), 3.05(t, 2H)
The endoparasite control agent of the t invention has
excellent anti-endoparasite effect, and exerts appropriate
controleffectagainstendoparasites. Theanimalforwhichthe
endoparasite control agent of the present invention can be used
is a human and an animal of non-human mammalian or avian species .
ary members of the non-human mammalian species include
ic animals, such as pigs, horses, cattle, sheep, goats,
rabbits, camels, water buffalos, deer, mink and chinchillas;
pet s, such as dogs, cats, little birds and.monkeys; and
experimental animals, such as rats, mice, golden hamsters and
guinea pigs. Exemplary members of the avian species include
domestic fowls, such as chickens, ducks, aigamo ducks
(crossbreeds of wild and domestic ducks), quails, domestic
ducks, geese and s.
Human rasites against which the rasite l
agent of the present invention is effective are roughly
classified into protozoa and helminths. Examples of the
protozoa include, but are not limited.thereto, Rhizopoda, such
as Entamoeba histolytica; Mastigophora, such as ania,
Trypanosoma and Trichomonas; oea, such as Plasmodium and
Toxoplasma; and Ciliophora, such as Balantidium coli.
Examples of the helminths include, but are not limited thereto,
Nematoda, such as Ascaris lumbricoides, Anisakis, Toxocara
canis, Trichostrongylus spp., Enterobius vermicularis,
hookworms (for example, Ancylostoma ale, Necator
americanus, Ancylostoma braziliense, etc.), Angiostrongylus
spp., Gnathostoma spp., filarial worms (filaria, Wuchereria
bancrofti. Brugia malayi , etc. ) , Onchocerca volvulus ,
Dracunculus nsis, Trichinella spiralis and
Strongyloides stercoralis ; Acanthocephala , such as
Macracan thorhynchus hirudinaceus; Gordiacea, such as
Gordioidea; Hirudinea, such as Hirudo nipponia; Trematoda, such
as Schistosoma japonicum, Schistosoma mansoni, Schistosoma
haematobium, chis sinensis, Heterophyes heterophyes,
Fasciola spp. and Paragonimus spp.; and Cestoda, such as
Diphyllobothrium latum, Sparganum mansoni, Sparganum
proliferum, Diplogonoporus grandis, Taeniidae (for example,
Taeniarhynchus saginatus, Taenia solium, Echinococcus, etc. ) ,
Hymenolepis spp., diunzcaninum, Mesocestoides.lineatus,
Bertiella spp. and nia surmenicola.
Non-human mammalian or avian endoparasites against which
the rasite control agent of the present invention is
effective are roughly classified into protozoa and.helminths.
Examples of the protozoa include, but are not limited thereto,
Apicomplexa, such.as Coccidia (for‘example, Eimeria, ra,
Toxoplasma, Neospora, Sarcocystis, Besnoitia, Hammondia,
Cryptosporidium, Caryospora, etc.), Haemosporina (for example,
Leucocytozoon, dium, etc.), Piroplasma (for example,
Theileria, Anaplasma, Eperythrozoon, Haemobartonella,
Ehrlichia, etc.), and others (for example, Hepatozoon,
Haemogregarina , etc. ) ; Microspora, such as Encephalitozoon and
NOsema; Mastigophora, such as Trypanosomatina (for example,
Trypanosoma, Leishmania, etc.), Trichomonadida (for example,
Chilomastix, Trichomonas, Monocercomonas, Histomonas, etc.),
and onadida (for example, Hexamita, Giardia, etc.);
Sarcodina , such as Amoebida (for example
, Entamoeba histolytica
(Entamoeba) etc.); and Ciliophora, such as Balantidium coli
(Balantidium), Buxtonella and Entodinium.
Examples of the helminths include, but are not limited
thereto, de, such as Ascaridida (for e, Ascaris
suum (Ascaris), Toxocara canis and Toxocara cati (Toxocara),
Toxascaris leonina (Toxascaris), Parascaris equorum
(Parascaris), Ascaridia galli (Ascaridia), Heterakis
gallinarwn(Heterakis),Anisakis,etc.),Oxyurida(forexample,
Oxyuris equi (Oxyuris), Passalurus ambiguus (Passalurus),
etc.), Strongylida (for example, Strongylus vulgaris
(Strongyflus), Haemonchus contortus (Haemonchus), agia
ostertagi (Ostertagia), Trichostrongylus colubriformis
(Trichostrongylus) , Cooperia punctata (Cooperia) , Nematodirus
filicollis (Nematodirus), Hyostrongylus rubidus
(Hyostrongylus), agostomum.radiatum (Oesophagostomum),
Chabertia ovina (Chabertia), Ancylostoma caninum
(Ancylostoma), Uhcinaria stenocephala (Uhcinaria), Nacator
americanus (Nantor), omum tomum (Bunostomum),
Dictyocaulus Viviparus (Dictyocaulus), Metastrongylus
elongatus (Metastrongylus), Filaroides hirthi (Filaroides),
strongylus abstrusus (Aelurostrongylus),
Angiostrongylus cantonensis (Angiostrongylus), Syngamus
trachea (Syngamus), Stephanurus dentatus (Stephanurus), etc.),
Rhabditida (for example, Strongyloides stercoralis
(Strongyloides), Micronema, etc.), Spirurida (for example,
Thelazia.rhodesi (Thelazia), OxyspiruraJnansoni (Oxyspirura),
erca lupi (Spirocerca), onema pulchrum
(Gongyionema), Draschia megastama (Draschia), ema
2O microstoma (Habronema), ps strongylina (Ascarops),
Physaloptera tialis (Physaloptera), Gnathostoma
spinigerum (Gnathostoma), etc.), Filariida (for example,
Dirofilaria immitis ilaria), Setaria equina (Setaria),
Dipetalonema, laria multipapillosa (Parafilaria),
Onchocerca cervicalis (Onchocerca), etc.), and Enoplida (for
example, Parafilaria bovicola (Parafilaria), Stephanofilaria
okinawaensis (Stephanofilaria), Trichuris vulpis (Trichuris),
Capillaria bovis (Capillaria), Trichosomoides crassicauda
(Trichosomoides), Trichinella spiralis (Trichinella),
Dioctophyma renale (Dioctophyma), etc.); Trematoda, such as
Fasciolata (for example, Fasciola hepatica (Fasciola),
Fasciolopsis buski (Fasciolopsis), etc.), Paramphistomatidae
(for example, gaster paloniae (Hbmalogaster), etc.),
Dicrocoelata (for e, Eurytrema pancreaticum (Eurytrema)
oelium dendritioum (Dicrocoelium), etc.), Diplostomata
(for example, Pharyngostomum cordatum (Pharyngostomum),
Alaria, etc.), Echinostomata (for e, Echinostoma
hortense (Echinostoma), Echinochasmus, etc.),
Troglotrematoidea (for example, lung flukes (Paragonimus),
yetus salmincola (Nanophyetus), etc.), Opisthorchiida
(for example, Clonorchis sinensis rchis) etc.),
Heterophyida (for example, Heterophyes heterqphyes
(Heterophyes), nimus yokogawai (Metagonimus), etc.),
Plagiorchiida (for example, Prosthogonimus ovatus
(Prosthogonimus) etc.), and Schistosomatidae (for example,
Schistosoma japonicum (Schistosoma) etc.); a, such as
Pseudophylidea (for example, Diphyllobothrium nihonkaiense
(Diphyllobothrium), Spirometra erinacei (Spirometra), etc.),
and Cyclophyllidea (for example, Anoplocephala perfoliata
(Anoplocephala), Paranoplocephala mamillana
(Paranoplocephala), Mbniezia benedeni (Mbniezia), Dipylidium
caninum(Dipylidiwn),Mesocestoideslineatus(Mbsocestoides),
Taenia pisiformis and Taenia hydatigena (Taenia), Hydatigera
taeniaeformis (Hydatigera), MUlticeps eps (Multiceps),
Echinococcus granulosus (Echinococcus), Echinococcus
multilocularis (Echinococcus), ibenia solium (Taenia),
Taeniarhynchus saginatus (Taeniarhynchus), Hymenolepis
diminuta (Hymenolepis), vampirolepis nana (vampirolepis),
Raillietina tetragona (Raillietina) , Amoebotaenia sphenoides
(Amoebotaenia) , etc. ) ; Acanthocephala, such as
Macracanthorhynchus hirudinaceus (Macracanthorhynchus) and
formis moniliformis (Moniliformis); Linguatulida, such
as Linguatula serrata (Linguatula): and other various
parasites.
In different designations, examples of the helminths
include, but are not limited to, Nematode, such as da (for
example,Ziichurisspp.,capillariaspp.,Trichomosoidesspp.,
ikichinellaspp.,etc.),Rhabditia(forexample,Micronemaspp.,
Strongyloides spp., etc.), ylida (for example,
Strongylus spp., Triodontophorus spp., Oesophagodontus spp.,
Trichonema spp., Gyalocephalus spp., cylindropharynx spp.,
Poteriostomum spp., Cyclococercus spp., Cylicostephanus spp.,
Oesophagostomum spp., Chabertia spp., nurus spp.,
Ancylostoma spp., Uhcinaria spp., Bunostomum spp.,
Globocephalus spp., Syngamus spp., Cyathostoma spp.,
Metastrongylus spp., Dictyocaulus spp., Mnellerius spp.,
Protostrongylus spp., Neostrongylus spp., Cystocaulus spp.,
Pneumostrongylus spp., Spicocaulus spp., Elaphostrongylus
spp., ParelaphostrongleS'spp., Crenosoma spp., Paracrenosoma
spp., Angiostrongyius spp.,.Aelurostrongylus spp., Filaroides
spp., laroides spp., Trichostrongylus spp., Haemonchus
spp., Ostertagia spp., Marshallagia spp., Cooperia spp.,
Nematodirus spp., Hyostrongylus spp., Obeliscoides spp.,
Amidostomum spp., nus spp., etc.),
Oxyurida (for e, Oxyuris spp., Enterobius spp.,
Passalurus spp. , Syphacia spp. , Aspiculuris spp. ,
Heterakis
spp. , etc. ) , Ascaridia (for example, Ascaris spp. , aris
spp. , Toxocara spp. , Parascaris spp. , Anisakis spp. , dia
spp. , etc. ) , Spirurida (for example, Gnathostoma
spp. ,
Physaloptera spp. , Thelazia spp. , Gongylonema spp. , Habronema
spp. , Parabronema spp. , Draschia spp . , Dracunculus spp. , etc. ) ,
and Filariida (for example, Stephanofilaria spp. , Parafilaria
spp. , Setaria spp. ,
Loa spp. , Dirofilaria spp. , Litomosoides
spp., Brugia spp. ,
Wuchereria
spp. ,
Onchocerca spp., etc.);
Acanthocephala (for example, Filicollis spp. , Moniliformis
spp. , Macracanthorhynchus spp. ,
Prosthenorchis
spp. ,
etc. ) ;
Trematoda including subclasses , such as Monogenea (for example ,
Gyrodactylus spp. , Dactylogyrus spp. , Polystoma spp. , etc. ) and
a (for example, Diplostomum spp . , Posthodiplostomum spp. ,
Schistosoma spp. , Trichobilharzia spp . , Ornithbilharzia spp. ,
Austrobilharzia spp. , Gigantobilharzia spp.
, Leucochloridium
spp. , Brachylaima spp. , Echinostoma spp. , Echinoparyphium spp . ,
Echinochasmus
spp. , Hypoderaeum spp. ,
Fasciola
spp. ,
Fasciolides
spp. , Fasciolopsis spp. , oelum spp. ,
coelum spp. , Paramphistomum spp. , phoron spp. ,
Cotylophoron spp. , Gigantoctyle spp. , Fischoederius
spp. ,
Gastrothylacus spp. , Notocotylus spp. , Catatropis spp. ,
Plagiorchis spp. , Prosthogonimus spp. , Dicrocoelium
spp. ,
Eurytema spp. , Troglotrema spp. , nimus spp. , Collyriclum
spp. , Nanophyetus spp. , Opisthorchis spp. ,
Clonorchis
spp. ,
Metorchis
spp. , Heterophyes spp. , Metagonimus spp. , etc. ) ;
Cestoda , such as Pseudophyllidea (for example ,
Diphyllobothrium spp. , Spirometra spp. , Schistocephalus spp. ,
Ligula spp. , Bothridium spp. , Diplogonoporus spp. ,
etc. ) , and
Cyclophyllidea (for example,
Mesocestoides
spp. ,
Anoplocephala spp. , Paranoplocehala spp. ,
Moniezia
spp. ,
osomsa spp. , Thysaniezia spp. , lina spp. , ia
spp. , Cittotaenia spp . , Andyra spp. ,
Bertiella
spp. ,
Taenia
spp. , Echinococcus
spp. , Hydatigera spp. ,
Davainea
spp. ,
Raillietina spp. , Hymenolepis spp. , Echinolepis spp. ,
Echinocotyle spp. , Diorchis spp. , Dipylidium spp. , Joyeuxiella
spp. , Diplopylidium spp. , etc . ) ; and others including parasites
belonging to Acanthocephala and Linguatulida.
The endoparasite control agent of the present invention is
effective against not only parasites that live in the body of
an intermediate or final host, but also parasites that live in
the body of a reservoir host . The compound ented by the
general a (I) of the present invention is effective at
every developmental stage of tes. For example, in the
case of protozoa, the compound is effective against their cysts
precystic forms and trophozoites; schizonts and amoeboid forms
at the l stage; gametocytes, gametes and zygotes at the
sexual stage; sporozoites; etc. In the case of nematodes, the
compound is effective against their eggs, larvae, and adults.
The compound of the present invention is capable of not only
combating parasites in the living body, but also even preventing
parasitic infection by application to the environment as a route
of infection. For example, soil-borne infection, i.e.
infection from soil of crop fields and parks; percutaneous
infection from water in rivers, lakes, s, paddy fields,
etc. ; oral infection from feces of animals such as dogs and cats;
oral infection from saltwater fish, freshwater fish,
crustaceans, shellfish, raw meat of domestic animals, etc.;
infection from mosquitoes , gadflies , flies , cockroaches
, mites ,
fleas, lice, assassin bugs, trombiculid mites, etc.; and the
like can be prevented from occurring.
The endoparasite control agent of the present invention can
be administered as a pharmaceutical for treatment or prevention
of'parasitosis in humans and animals of non~human1nammalian or
avian species. The mode of administration may be oral or
parenteral administration. In the case of oral administration,
the endoparasite control agent of the present invention can be
stered, for example, as a capsule, a tablet, a pill, a
powder, a granule, a fine granule, a powder, a syrup, an
c-coated preparation, a suspension or a paste, or after
blended in a liquid drink or feed for animals. In the case of
parenteral administration, the endoparasite control agent of
the present invention can be stered in a dosage form which
allows sustained mucosal or percutaneous absorption, for
example, as an injection, an infusion, a suppository, an
emulsion, a suspension, a drop, an nt a cream, a solution,
a lotion, a spray, an aerosol, a cataplasm or a tape.
In the case where the rasite control agent of the
present invention is used as a pharmaceutical for humans and
animals of man mammalian or avian s, the optimum
amount (effective amount) of the active ingredient varies with
the purpose (treatment or prevention), the kind of infectious
parasite, the type and severity of infection, the dosage form,
etc., but in general, the oral daily dose is in the range of
about 0 . 0001 to 10000 mg/kg body weight and the parenteral daily
dose is in the range of about 0.0001 to 10000 mg/kg body weight,
and such a dose may be administered as a single dose or d
doses.
The concentration of the active ingredient in the
endoparasite control agent of the t invention is
generally about 0.001 to 100% by mass, preferably about 0.001
to 99% by mass , and more ably about 0 . 005 to 20% by mass.
The endoparasite control agent of the present invention may be
a composition that can be ly administered, or a highly
concentrated composition that is used for administration after
diluted to a suitable concentration.
For the purpose of reinforcing or complementing the effect
of the endoparasite control agent of the present invention, a
ed use with any existing endoparasite control agent is
possible. In such a combined use, two or more active
ingredients may be mixed and formulated into a preparation
before administration, or two or more different preparations
may be administered separately.
EXAMPLES
Next, the present invention will be illustrated in detail
by formulation examples and test examples of the endoparasite
control agent of the present invention, but the scope of the
present invention is not limited by the following formulation
examples and test examples.
Formulation e 1 (emulsion)
Ten parts of the carboxamide derivative represented.by the
general formula (I) of the present invention, 6 parts of Sorpol
3555 (surfactant, manufactured by Toho Chemical ry)
, and
84 parts of Solvesso 150 (manufactured.by Exxon) are uniformly
mixed with stirring to give an emulsion.
Formulation Example 2 (ointment)
One part of the carboxamide derivative represented by the
general formula (I) of the present ion, 50 parts of white
beeswax, and 49 parts of white petrolatum are well mixed to give
an ointment.
Formulation Example 3 (tablet)
Two parts of the carboxamide tive represented.by the
general formula (I) of the present invention, 10 parts of
vegetable oil (olive oil), 3 parts of crystalline cellulose,
20 parts of white carbon, and 65 parts of kaolin are well mixed
and compressed into a tablet.
Formulation Example 4 (injection)
Ten.parts of the carboxamide derivative represented.by the
general formula (I) of the present ion, 10 parts of
propylene glycol for use as a food additive, and 80 parts of
vegetable oil (corn oil) are mixed to give an injection.
Formulation e 5 (solution)
Five parts of the carboxamide derivative represented by the
general formula (I) of the present invention, 20 parts of
surfactant, and 75 parts of ion exchanged water are well mixed
to give a solution.
Test Example 1 (in vitro measurement of inhibitory activity on
Ascaris suum succinate—ubiquinone reductase (mitochondrial
complex 11))
To a solution containing 50 mM potassium phosphate (pH 7 .4)
and 0.1% (w/v) sucrose monolaurate, an electron acceptor
ubiquinone-z (UQz) was added at a final concentration of 60 MM,
and the mixture was allowed to stand at 25°C for 20 s.
To this, potassium cyanide (final concentration: 2 mM) and
mitochondria prepared from adult Ascaris suum muscle were added,
and thorough mixing was done. To aliquots of the mixture, an
inhibitor to be tested was added at various concentrations, and
the mixtures were allowed to stand at 25°C for 3 minutes. The
enzymatic on was ted by addition of potassium
succinate (final concentration: 10 mM) . The enzymatic
activity was calculated based on the measurement of change in
the absorbance at 278 nm of UQz (a = 1.5x104 l), and ICso
was determined from the plot of the inhibition percentage
t the inhibitor tration.
Test Example 2 (in vitro ement of inhibitory activity on
porcine succinate—ubiquinone reductase (mitochondrial complex
II))
To a solution containing 50 mM potassium phosphate (pH 7 .4)
and 0.1% (w/v) sucrose monolaurate, an electron acceptor
ubiquinone-2 (UQZ) was added at a final concentration of 60 MM,
and the e was allowed to stand at 25°C for 20 minutes.
To this, potassium e (final concentration: 2 mM) and
mitochondria prepared from porcine heart muscle were added, and
thorough mixing was done. To aliquots of the mixture, an
inhibitor to be tested was added at various concentrations
, and
the es were allowed to stand at 25°C for 3 s. The
enzymatic reaction was initiated by on of potassium
succinate (final concentration: 10 mM). The enzymatic
activity was calculated based on the measurement of change in
the absorbance at 278 nm of U02 (8 1.5x10“ M‘lcm'l), and Ic50
was determined from the plot of the inhibition percentage
against the inhibitor concentration.
The results are shown in Table 5. In the table, “-”
tes “not tested,” and “Ascaris suum ICso value (A)”
indicates an Icw value (50% inhibitory concentration) for
inhibition of succinate-ubiquinone reductase (mitochondrial
complex II) of s suum. From the extent of inhibition of
this respiratory enzyme, the parasite control activity can be
estimated. “Porcine mitochondria ICm,value (8)” indicates an
Icm value for inhibition of succinate-ubiquinone reductase
(mitochondrial complex II) of the host pig. From the extent
of inhibition of this respiratory enzyme, the influence on the
host can be estimated. A greater selectivity index B/A
indicates a higher safety for the host.
Table 6
Ascaris suum Porcine ondria Selectivity
No. ICsovalue(A) ICsovalue(B) B/A
iii nn no inhibition at 90 MM
no inhibition at 90 pM
iii ii no inhibition at 90 [.LM
iii in no inhibition at 9 pM
no inhibition at 9 MM
1~llO 4.07 nM no inhibition at 10 1114
iii in no inninininn ii in in
iii ii no inhibition at 90 pm
ii iii in
mm no inhibition at 90 [.LM
70.5 nM no inhibition at 90 [AM
inn nn no inhibition at 9 uM
_N-\I 14 nM no inhibition at 90 11M
no inhibition at 90 uM
3-7 90 w
4-1 3.44 nM
3% I N 5.15 nM
#h I L0 1.98 nM
8.36 nM
6.07 nM
Ih l 0‘ 8.34 nM no inhibition at 9 pM
#8 I \l 1.78 nM w
2.61 nM
As is clear from the results in Table 5, the carboxamide
derivatives represented by the general a (I) of the
present invention and salts thereof showed a strong inhibitory
activity on the parasitic succinate—ubiquinone reductase
(mitochondrial complex II) (ICso values: 1.21 to 127 nM) , but
hardly affected the ty of succinate—ubiquinone reductase
hondrial complex II) of the host pig (more than 1 , GOO-fold
selectivity) . Therefore, the endoparasite control agent of
the present invention is not only highly active in parasite
control, but also highly safe for the host.
Test Example 3 (in vivo activity on Haemonchus contortus)
The test was conducted according to the larval migration
inhibition assay (LMIA: Demeler et al., 2010). A larval
suspension was prepared so as to contain 100 to 120 third-stage
larvae of Haemonchus contortus per 20 uL, and then 20 p21. of the
larval suspension was added to each well on a breeding plate
to which compound solutions ed to predetermined
concentrations were usly added at 1780 uL/well each. The
breeding plate was maintained for breeding at 28°C for 24 hours .
Meanwhile, to a plate for larval migration observation, 400 uL
of a 1.5% agar solution was added and left to stand until
coagulation. Then, the larvae were allowed to migrate through
a sieve from the breeding plate to the plate for larval migration
observation , and the plates were maintained for breeding at 28°C
for another 24 hours. The larvae which had migrated, and the
larvae which had not migrated were counted, the percentage of
migration inhibition was calculated, and the activity was
graded based on the following ion. All samples were
tested in duplicate, and the results are shown in Table 7. In
the table, “-” indicates “not tested.”
tage of migration inhibition
70 to 100%: A
40 to 69%: B
HAS510030NZPR
303788177
to 39%: C
lower than 10%: D
Table 7
Compound Concentration (ppm)
No. 100 10 1 0.1
1-16 B C C C
1-32 - B C C
2-1 - - B C
2-6 - C C C
3-7 B C C C
4-1 - C C C
4-7 B C C C
As is clear from the results in Table 7, the compounds proven
in the described in vitro test to have a strong activity
showed a strong activity in the in vivo test as well, and thus
the compound of the present invention is effective as an
endoparasite control agent.
Unless the context clearly requires otherwise, throughout
the ption and the claims, the words “comprise”,
“comprising”, and the like, are to be construed in an inclusive
sense as opposed to an exclusive or exhaustive sense, that is
to say, in the sense of “including, but not limited to”.
The reference to any prior art in the specification is not,
and should not be taken as, an acknowledgement or any form of
suggestion that the prior art forms part of the common general
knowledge in New Zealand.
HAS510030NZPR
303864629
Claims (8)
1. A method for controlling endoparasites, comprising orally or parenterally stering to a non-human mammal or bird an 5 effective amount of an rasite control agent comprising a carboxamide derivative represented by the general formula (I): wherein A represents a (C1-C8) alkylene group optionally 10 substituted by a halogen atom, a (C1-C6) alkyl group and/or a (C3-C6) cycloalkyl group; a (C1-C8) alkylene group which is optionally substituted by a halogen atom, a (C1-C6) alkyl group and/or a (C3-C6) cycloalkyl group and is modified by incorporation, into the carbon chain, of at least one heteroatom 15 selected from an oxygen atom, a sulfur atom, -SO-, -SO2- and -N(R)- in R represents a hydrogen atom, a (C1-C6) alkyl group, a (C3-C6) cycloalkyl group, a (C1-C6) alkylcarbonyl group or a (C1-C6) alkoxycarbonyl group); a (C2-C8) alkenylene group optionally substituted by a halogen atom, a (C1-C6) alkyl group 20 and/or a (C3-C6) cycloalkyl group; a (C2-C8) alkenylene group which is optionally substituted by a halogen atom, a (C1-C6) alkyl group and/or a (C3-C6) cycloalkyl group and is modified by incorporation, into the carbon chain, of at least one atom selected from an oxygen atom, a sulfur atom, -SO-, 25 -SO2- and -N(R)- (wherein R is as d above); a ) lene group optionally substituted by a halogen atom, a HAS510030NZPR 303864629 (C1-C6) alkyl group and/or a (C3-C6) cycloalkyl group; or a (C2-C8) alkynylene group which is optionally substituted by a halogen atom, a (C1-C6) alkyl group and/or a (C3-C6) cycloalkyl group and is ed by incorporation, into the carbon chain, 5 of at least one atom selected from an oxygen atom, a sulfur atom, -SO-, -SO2- and -N(R)- in R is as defined above), and in each case, A may form a cyclic structure, where le, E represents a hydrogen atom; a (C1-C6) alkyl group; a (C3-C6) cycloalkyl group; a (C1-C6) alkoxy (C1-C6) alkyl group; a (C1-C6) 10 arbonyl group; or a (C1-C6) alkoxycarbonyl group, each X may be the same or different, and represents a halogen atom; a cyano group; a nitro group; a (C1-C6) alkyl group optionally substituted by a halogen atom; a (C1-C6) alkoxy group optionally substituted by a halogen atom; a ) alkylthio 15 group optionally substituted by a halogen atom; a (C1-C6) alkylsulfinyl group optionally substituted by a halogen atom; or a (C1-C6) alkylsulfonyl group optionally substituted by a halogen atom, m represents an integer of 0 to 5, 20 each Y may be the same or different, and represents a halogen atom; a cyano group; a nitro group; a hydroxy group; a (C1-C6) alkyl group optionally substituted by a halogen atom; a (C2-C6) alkenyl group optionally tuted by a n atom; a (C2-C6) alkynyl group optionally tuted by a halogen atom; 25 a (C1-C6) alkoxy group optionally substituted by a halogen atom; a (C1-C6) alkoxy (C1-C6) alkoxy group; a (C2-C6) alkenyloxy group optionally substituted by a halogen atom; a (C2-C6) alkynyloxy group optionally substituted by a halogen atom; a (C1-C6) alkylthio group optionally tuted by a halogen atom; a HAS510030NZPR 303864629 (C1-C6) alkylsulfinyl group optionally substituted by a halogen atom; a ) alkylsulfonyl group optionally substituted by a halogen atom; a (C1-C6) alkoxycarbonyl group; a (C1-C6) alkoxyimino (C1-C3) alkyl group; a (C3-C30) trialkylsilyl group; 5 a mono(C1-C6) alkylsulfonylamino group optionally substituted by a halogen atom; a phenyl group optionally tuted by one or more substituents selected from group B substituents; a phenoxy group optionally substituted by one or more substituents selected from group B substituents; a heterocyclic 10 group optionally substituted by one or more substituents selected from group B substituents; or a heterocycloxy group optionally substituted by one or more substituents selected from group B substituents, the group B substituents are a n atom; a cyano group; 15 a nitro group; a (C1-C6) alkyl group optionally substituted by a halogen atom; a (C2-C6) alkenyl group optionally substituted by a halogen atom; a (C2-C6) alkynyl group optionally substituted by a halogen atom; a (C1-C6) alkoxy group ally substituted by a halogen atom; a ) alkenyloxy group 20 optionally substituted by a halogen atom; a (C2-C6) alkynyloxy group optionally substituted by a halogen atom; a ) hio group optionally substituted by a n atom; a (C1-C6) alkylsulfinyl group optionally substituted by a halogen atom; a (C1-C6) ulfonyl group optionally substituted by 25 a halogen atom; a (C1-C6) alkoxycarbonyl group; and a (C1-C6) alkoxyimino (C1-C3) alkyl group, n represents an integer of 0 to 5, with the proviso that when n is an integer of 2 to 5, two adjacent Y groups may join together to form a ) alkylene group; a (C3-C5) alkenylene HAS510030NZPR 303864629 group; a (C2-C4) alkyleneoxy group; or a (C1-C3) alkylene dioxy group optionally substituted by a halogen atom, and Z represents CH or CY in Y is as defined above), or a salt thereof as an active ingredient.
2. The method according to claim 1, wherein A represents a (C1-C8) ne group optionally substituted by a halogen atom, a (C1-C6) alkyl group and/or a (C3-C6) cycloalkyl group; or a (C1-C8) ne group which is 10 optionally substituted by a halogen atom, a (C1-C6) alkyl group and/or a (C3-C6) cycloalkyl group and is modified by incorporation, into the carbon chain, of at least one heteroatom selected from an oxygen atom, a sulfur atom, -SO-, -SO2- and -N(R)- (wherein R represents a hydrogen atom, a (C1-C6) alkyl 15 group, a (C3-C6) cycloalkyl group, a (C1-C6) alkylcarbonyl group or a (C1-C6) alkoxycarbonyl group).
3. The method according to claim 1, wherein A represents a (C1-C8) alkylene group optionally 20 substituted by a (C1-C6) alkyl group and/or a (C3-C6) cycloalkyl group; -CR1(R2)-CR3(R4)-Q- in R1, R2, R3 and R4 may be the same or different from each other, and represent a hydrogen atom, a (C1-C6) alkyl group or a (C3-C6) cycloalkyl group, or R1, R2, R3 and R4 may join together in any combination to form 25 a (C3-C6) lkane, and Q represents an oxygen atom, a sulfur atom, -SO-, -SO2- or -N(R)- (wherein R represents a hydrogen atom, a (C1-C6) alkyl group, a (C3-C6) cycloalkyl group, a ) alkylcarbonyl group or a ) alkoxycarbonyl group)); or -CR1(R2)-CR3(R4)-CR5(R6)-Q- (wherein R1, R2, R3, R4 and Q are as HAS510030NZPR 303864629 d above, and R5 and R6 may be the same or different from each other, and represent a hydrogen atom, a (C1-C6) alkyl group or a (C3-C6) cycloalkyl group, or R1, R2, R3, R4, R5 and R6 may join together in any combination to form a (C3-C6) cycloalkane).
4. The method according to claim 1, wherein A represents a (C1-C8) alkylene group optionally substituted by a (C1-C6) alkyl group and/or a (C3-C6) cycloalkyl group; -CR1(R2)-CR3(R4)-Q- (wherein R1, R2, R3 and R4 may be the 10 same or different from each other, and represent a hydrogen atom, a (C1-C6) alkyl group or a (C3-C6) cycloalkyl group, or R1, R2, R3 and R4 may join together in any combination to form a (C3-C6) cycloalkane, and Q ents an oxygen atom, a sulfur atom, -SO-, -SO2- or -N(R)- (wherein R represents a hydrogen 15 atom, a (C1-C6) alkyl group, a (C3-C6) cycloalkyl group, a (C1-C6) alkylcarbonyl group or a (C1-C6) alkoxycarbonyl group)); or -CR1(R2)-CR3(R4)-CR5(R6)-Q- (wherein R1, R2, R3, R4 and Q are as defined above, and R5 and R6 may be the same or different from each other, and represent a hydrogen atom, a (C1-C6) alkyl group 20 or a (C3-C6) cycloalkyl group, or R1, R2, R3, R4, R5 and R6 may join together in any combination to form a (C3-C6) lkane), E represents a hydrogen atom; a (C1-C6) alkyl group; a (C1-C6) alkylcarbonyl group; or a ) alkoxycarbonyl group, each X may be the same or different, and represents a n 25 atom; a ) alkyl group optionally tuted by a halogen atom; a (C1-C6) alkoxy group optionally substituted by a halogen atom; or a (C1-C6) alkylthio group optionally substituted by a halogen atom, m represents 1 or 2, HAS510030NZPR 303864629 each Y may be the same or different, and represents a halogen atom; a hydroxy group; a (C1-C6) alkyl group optionally substituted by a halogen atom; a (C1-C6) alkoxy group optionally substituted by a halogen atom; a (C1-C6) alkoxy ) alkoxy 5 group; a ) loxy group optionally substituted by a halogen atom; a mono(C1-C6) alkylsulfonylamino group optionally substituted by a halogen atom; a phenyl group optionally substituted by one or more substituents selected from a halogen atom, a cyano group, a nitro group, a (C1-C6) alkyl group 10 optionally substituted by a halogen atom, and a (C1-C6) alkoxy group optionally tuted by a halogen atom; a phenoxy group ally substituted by one or more substituents selected from a halogen atom, a cyano group, a nitro group, a (C1-C6) alkyl group optionally substituted by a halogen atom, and a 15 (C1-C6) alkoxy group optionally substituted by a halogen atom; a heterocyclic group optionally substituted by one or more substituents ed from a halogen atom, a cyano group, a nitro group, a (C1-C6) alkyl group optionally substituted by a halogen atom, and a (C1-C6) alkoxy group ally 20 substituted by a halogen atom; or a heterocycloxy group optionally substituted by one or more substituents ed from a halogen atom, a cyano group, a nitro group, a (C1-C6) alkyl group optionally substituted by a halogen atom, and a (C1-C6) alkoxy group optionally substituted by a halogen atom, 25 n represents an integer of 0 to 3, with the proviso that when n is 2 or 3, two adjacent Y groups may join together to form a (C2-C4) alkyleneoxy group or a (C1-C3) ne dioxy group optionally substituted by a halogen atom, and Z represents CH or CY (wherein Y is as defined above). HAS510030NZPR 303864629
5. The method according to claim 1, wherein A represents a (C1-C5) alkylene group optionally substituted by a (C1-C6) alkyl group and/or a (C3-C6) lkyl 5 group; -CR1(R2)-CR3(R4)-Q- (wherein R1, R2, R3 and R4 may be the same or different from each other, and represent a hydrogen atom, a (C1-C6) alkyl group or a (C3-C6) lkyl group, and Q represents an oxygen atom or a sulfur atom); or -CR1(R2)-CR3(R4)-CR5(R6)-Q- (wherein R1, R2, R3, R4 and Q are as 10 defined above, and R5 and R6 may be the same or different from each other, and represent a hydrogen atom, a (C1-C6) alkyl group or a (C3-C6) cycloalkyl group), E represents a en atom, each X may be the same or different, and represents a n 15 atom or a (C1-C6) alkyl group optionally substituted by a halogen atom, m represents 1, each Y may be the same or different, and represents a halogen atom or a (C1-C6) alkyl group optionally substituted by a halogen 20 atom, n represents an integer of 1 to 3, and Z represents CH or CY (wherein Y is as defined above).
6. A method for controlling endoparasites, sing orally 25 or parenterally administering an effective amount of the non-human mammal or bird endoparasite control agent as defined in any one of claims 1 to 5 to a man mammal.
7. The method according to claim 6, wherein the non-human mammal HAS510030NZPR 303908001 is a domestic animal.
8. A method for controlling endoparasites as claimed in any one of claims 1 to 7, substantially as hereinbefore described with 5 particular nce to any one or more of the examples.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011045042 | 2011-03-02 | ||
| JP2011-045042 | 2011-03-02 | ||
| PCT/JP2012/055190 WO2012118139A1 (en) | 2011-03-02 | 2012-03-01 | Internal parasiticide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ613343A NZ613343A (en) | 2015-09-25 |
| NZ613343B2 true NZ613343B2 (en) | 2016-01-06 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012224015B2 (en) | Internal parasiticide | |
| US9562034B2 (en) | Endoparasite control agent | |
| US10017490B2 (en) | Endoparasite control agent and method for using the same | |
| NZ613343B2 (en) | Internal parasiticide |